Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on Lorundrostat
3 evidence topics · 4 sources
Mineralocorticoid receptor antagonists, potassium-sparing diuretics, and epithelial sodium channel inhibitors: prohibited in the trials
“The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Background renin-angiotensin system inhibitors and SGLT2 inhibitors: serum potassium and eGFR
“were placed on a standardized antihypertensive regimen that included a high-dose angiotensin receptor blocker prior to randomization; greater increases in serum potassium level and decreases in eGFR were observed compared with those in the current trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical drug-drug interaction studies
No evidence found.